On Monday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Molycorp, Inc. (NYSE:MCP), Darden Restaurants, Inc. (NYSE:DRI), Calithera Biosciences, Inc. (NASDAQ:CALA), Capnia, Inc. (NASDAQ:CAPN)
Molycorp, Inc. (NYSE:MCP), with shares inclined 26.36%, closed at $0.45.
Darden Restaurants, Inc. (NYSE:DRI), with shares jumped 3.70%, settled at $69.22, hitting new 52-week high of $70.
Calithera Biosciences, Inc. (NASDAQ:CALA), with shares climbed 18.98%, and closed at $18.74.
Capnia, Inc. (NASDAQ:CAPN), surged 17.50%, and closed at $6.31.
Latest NEWS regarding these Stocks are depicted underneath:
Molycorp, Inc. (NYSE:MCP)
Formerly on March 16, Molycorp, Inc. (MCP), declared financial and operating results for the fourth quarter and full year 2014.
FOURTH QUARTER 2014 RESULTS:
The Corporation stated merged net proceeds of $116.2 million, a 6% decrease over the third quarter of 2014. The decrease in proceeds was largely driven by a shifting product mix, lower sales volumes from all segments, except for Rare Metals’, and softened pricing for rare earths.
Molycorp stated a loss attributable to ordinary stockholders of $329.8 million, or $1.43 per share. Adjusted loss per share of $0.39 in the fourth quarter of 2014 does not reflect impairment charges for goodwill and other intangible assets, out-of-ordinary business expenses, and certain other non-cash items.
FULL YEAR 2014 RESULTS:
The Corporation stated merged net proceeds of $475.6 million, a 14% decrease as contrast to the full year 2013. The decrease in proceeds was largely driven by softened rare earth pricing.
Molycorp stated a full year loss attributable to ordinary stockholders of $607.8 million, or $2.70 per share. Adjusted loss per share of $1.31 for the full year 2014 eliminates the effect of operational expansion items, out-of-ordinary business expenses, and certain other non-cash items
Molycorp, Inc. produces and sells rare earths and rare metal materials in the United States and internationally. The corporation’s Resources segment extracts rare earth minerals, counting light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium-praseodymium; heavy rare earth concentrates, which comprise samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX and PhosFIX, a line of rare earth-based water treatment products.
Darden Restaurants, Inc. (NYSE:DRI)
Darden Restaurants, Inc. (DRI), stated its financial results for the third quarter ended February 22, 2015.
Third Quarter 2015 Financial Highlights As compared to Same Period a Year Ago:
- Total sales from ongoing operations in the third quarter raised 6.9% to $1.73 billion
- Adjusted earnings per diluted share* raised 39% to $0.99
- On a GAAP basis, earnings per diluted share raised 55% to $1.01
- Combined Darden comparable same-restaurant sales for the quarter were +3.6%:
- +2.2% for Olive Garden
- +5.4% for LongHorn Steakhouse
- +5.4% for Yard House
- +6.1% for The Capital Grille
- +5.2% for Seasons 52
- +3.2% for Bahama Breeze
- +9.6% for Eddie V’s
- The corporation projects fourth quarter earnings per diluted share of $0.91 to $0.94
- The Board of Directors declared a regular dividend of $0.55 per share to be paid in the fourth quarter.
Adjustments to Earnings Per Share:
- Stated net earnings per diluted share from ongoing operations for the third quarter were positively influenced by about $0.02. This comprises about:
- +5 cents of tax benefits related to the final disposition of our interest in the aquaculture investment
- -2 cents related to impairments of excess land parcels held for sale
- -1 cent for other planned action costs associated with the evaluation of our real estate portfolio
- Not including adjustments, earnings per diluted share were $1.01.
Darden Restaurants, Inc. owns and operates full service restaurants in the United States and Canada. It operates restaurants under the Olive Garden, LongHorn Steakhouse, Bahama Breeze, Seasons 52, The Capital Grille, Eddie V’s, and Yard House brand names. As of July 28, 2014, it owned and operated about 1,500 restaurants. The corporation was founded in 1968 and is headquartered in Orlando, Florida.
Calithera Biosciences, Inc. (NASDAQ:CALA)
Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical corporation focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, declared that the Corporation’s fourth quarter and year-end 2014 financial results will be released on Thursday, March 26, 2015. Corporation administration will host a conference call on Thursday, March 26, 2015 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to talk about the financial results and other recent corporate highlights.
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical corporation, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate comprises CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma.
Capnia, Inc. (NASDAQ:CAPN)
Formerly, on 10th of this month, Capnia, Inc. (CAPN), declared financial results for the fourth quarter and twelve months ended December 31, 2014.
“Capnia accomplished several important milestones in 2014, counting a successful initial public offering and the launch of CoSense(R), the only device accessible for accurate assessment of end-tidal carbon monoxide (ETCO) in newborns,” said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. “The commercial rollout of CoSense is proceeding in the U.S. We also continue to evaluate the potential of our therapeutic nasal CO2 technology for the treatment of symptomatic allergic rhinitis, cluster headache and trigeminal neuralgia (TN). This is an exciting time for the Corporation, and we look forward to communicating our progress throughout 2015.”
Fourth Quarter 2014 Financial Results:
No proceed was recognized in the three months ended December 31, 2014 or December 31, 2013.
Research and development expenses in the fourth quarter of 2014 were $0.6 million, contrast to $0.4 million in the fourth quarter of 2013. The raise was primarily due to reimbursement of R&D expense of $0.3 million under the GSK license contract in the fourth quarter of 2013. The GSK license contract was terminated in the second quarter of 2014. Exclusive of this reimbursement R&D expenses were largely constant in both quarters.
Sales and marketing expenses in the fourth quarter of 2014 were $0.2 million. There were no sales and marketing expenses for the year ended December 31, 2013. The raise was primarily due to the addition of the Vice President of Sales in June 2014 and the commercial launch activities for CoSense initiated in October 2014.
General and administrative expenses in the fourth quarter of 2014 raised to $1.1 million, contrast to $0.2 million in the fourth quarter of 2013. The raise was primarily due to an raise in consulting costs, employee related costs due to raised headcount and an raise in stock based compensation expense of $0.3 million in 2014 as compared to 2013.
Interest expense raised by $1.9 million in the fourth quarter of 2014 contrast to the fourth quarter of 2013. This raise was primarily due to the write-off of the unamortized balance of the debt discount associated with the 2014 convertible notes as of November 18, 2014 (the IPO date).
Other expense in the fourth quarter of 2014 raised by $3.6 million contrast to the fourth quarter of 2013. This raise was due to an raise of $5.8 million in the fair value of the Series B warrant liability from November 18, 2014 to December 31, 2014, and a net decrease of $2.2 million in the fair value of other stock warrants.
Net loss for the fourth quarter of 2014 was $7.9 million, or a loss of $2.23 per share, contrast to a net loss of $1.0 million, or a loss of $1.82 per share, for the fourth quarter of 2013.
Cash, cash equivalents, and marketable securities at December 31, 2014 totaled $8.0 million. This contrast to $1.3 million at December 31, 2013.
Capnia, Inc. develops and commercializes therapeutics and diagnostics products. The corporation offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has accomplished Phase II clinical trials for the treatment of symptoms related to allergic rhinitis. The corporation was founded in 1999 and is based in Redwood City, California.
Full Year 2014 Financial Results:
There was no proceed for the twelve months ended December 31, 2014, contrast to $3.0 million for the twelve months ended December 31, 2013. The $3.0 million of proceed in the fiscal year ended December 31, 2013 represented the proceed from the license contract with GSK.
Research and development expenses for the twelve months ended December 31, 2014 reduced 6% to $2.2 million, contrast to $2.4 million for the same period in 2013. The decrease was primarily due to employee related costs due to lower headcount in 2014 as compared to 2013.
Sales and marketing expenses for the twelve months ended December 31, 2014 were $0.3 million. There were no sales and marketing expenses for the year ended December 31, 2013. The raise was primarily due to the addition of the Vice President of Sales in June 2014 and commercial launch activities for CoSense.
General and administrative expenses for the twelve months ended December 31, 2014 raised 82% to $2.7 million, contrast to $1.5 million for the same period in 2013. The raise was primarily due to an raise in consulting costs, employee related costs, counting stock compensation expense of $0.3 million, due to raised executive headcount in 2014 as compared to 2013.
Interest expense raised by $1.3 million for the twelve months ended December 31, 2014 contrast to the same period in 2013. This raise was primarily due to the write-off of the unamortized balance of the debt discount associated with the 2014 convertible notes as of November 18, 2014 (the IPO date).
Other expense for the twelve months ended December 31, 2014 raised by $4.6 million contrast to the same period in 2013. This raise was due to an raise of $5.8 million in the fair value of the Series B warrant liability from November 18, 2014 to December 31, 2014, offset by a net decrease of $1.2 million in the fair value of other stock warrants.
Net loss for the twelve months ended December 31, 2014 was $13.9 million, or a loss of $10.92 per share, contrast with a net loss of $3.7 million, or a loss of $5.10 per share, for the same period in 2013.
Capnia, Inc. develops and commercializes therapeutics and diagnostics products. The corporation offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to degradation of red blood cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
